The Globe and Mail reports in its Tuesday edition that Lunenfeld-Tanenbaum Research Institute senior investigator Daniel Drucker and colleagues are studying the mechanisms behind the seemingly endless uses of Ozempic and its cousins in the class known as glucagon-like peptide-1 receptor agonists, or GLP-1s. The Globe's Kelly Grant and Kasia Mychajlowycz write that Dr. Drucker and his lab have received funding from Novo Nordisk, the Danish company that makes Ozempic and Wegovy. Their insights could help medical scientists and pharmaceutical companies design better Ozempic offshoots in the future. Rola Hammoud, another scientist in Dr. Drucker's lab, is pleased with what the current generation of drugs is already capable of. Dr. Hammoud says: "These GLP-1 drugs really just highlight how, if you can just override your biology, how much of an effect you get. Weight loss and appetite control is not simply a willpower problem, but it is actually a more complex physiological process."